Document Type

Article

Publication Date

4-2026

Identifier

DOI: 10.1002/jcph.70168; PMCID: PMC13033967

Abstract

Atomoxetine, a selective norepinephrine reuptake inhibitor, is a nonstimulant alternative to treat attention-deficit/hyperactivity disorder in children and adolescents. Atomoxetine exposure is highly variable due to cytochrome P450 polymorphism; however, the impact of these genetic variations has not been adequately characterized in the pediatric population. A population pharmacokinetic (PK) model was developed to evaluate steady-state atomoxetine exposures after oral administration in a large, heterogeneous population of children and adolescents with different metabolic phenotypes. Due to the highly variable and complex absorption between subjects and occasions, a two-stage approach was implemented, treating each participant/occasion as a separate individual. First, the individual atomoxetine parameters were estimated using a one-compartment distribution model with zero-order duration into a depot compartment followed by first-order absorption into the central compartment with linear elimination. Next, population-level parameters were obtained, and covariate analysis was performed. Using actual body weight, relative bioavailability based on CYP2D6 or CYP2C19 phenotype, and CYP2D6 clearance effects in the model reduced the variability from 81.6% to 64.5% and 92.4% to 75.5% for apparent volume and apparent clearance, respectively. The final model showed adequate precision in PK parameters and accuracy in exposure metrics. Following prospective validation, this model could be used to provide clinicians with individualized dosing targets when prescribing atomoxetine to children and adolescents based on their genetic disposition.

Journal Title

Journal of clinical pharmacology

Volume

66

Issue

4

First Page

70168

Last Page

70168

MeSH Keywords

Humans; Atomoxetine Hydrochloride; Child; Attention Deficit Disorder with Hyperactivity; Adolescent; Male; Adrenergic Uptake Inhibitors; Female; Models, Biological; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2C19; Biological Availability; Administration, Oral

PubMed ID

41906544

Keywords

ADHD; CYP2C19; CYP2D6; atomoxetine; pediatrics; population pharmacokinetics

Comments

Grants and funding

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

Publisher's Link: https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.70168

Download

Share

COinS